#United Kingdom #Piramal Pharma #Morpeth Facility #Morpeth #Korsch X3

Celebrating 20 Years of Excellence: Piramal Pharma Solutions and the Korsch X3 Tablet Press

As Piramal Pharma Solutions commemorates two decades of service at its Morpeth facility, it has taken a significant step forward by acquiring a cutting-edge Korsch X3 tablet press. This investment not only marks an important milestone in the company's history but also showcases its commitment to advancing pharmaceutical manufacturing technology.

A Milestone Investment

Piramal Pharma Solutions, recognized as one of the leading global Contract Development and Manufacturing Organizations (CDMO), recently celebrated its 20th anniversary in Morpeth, UK. To mark this occasion, the company proudly announced the installation of a Korsch X3 tablet press—an innovation tailored to meet the evolving needs of pharmaceutical development and production. The new press features a comprehensive level 5 safety system, essential for the secure and enclosed manufacturing of potent medications at both clinical and commercial scales.

The Korsch X3 tablet press, equipped with a DryCon containment kit, enables Morpeth to respond swiftly to the burgeoning demand for complex therapies. Peter DeYoung, CEO of Piramal Global Pharma, stated, "This acquisition is an ideal way to celebrate our 20 years of excellence in pharmaceutical production and emphasizes our steadfast commitment to enhancing and prolonging patients' lives across the globe."

Advanced Manufacturing Capabilities

The introduction of the Korsch X3 marks a leap in Morpeth's manufacturing capabilities, particularly in producing high-potency active pharmaceutical ingredients (HPAPIs). Designed specifically for this purpose, the Korsch X3 can produce tablets up to 25 mm in size and enhances the range of formulations that can be manufactured at the site. This development promises improved operational efficiency and tablet strength, vital properties for meeting rigorous healthcare standards.

Unlike traditional tablet presses that require open handling of materials, the Korsch X3 allows for a closed feeding system using transport containers equipped with hygienic connections. This feature, combined with a closed discharge channel, directs the tablet cores straight to the coating facility, thereby streamlining the production process while minimizing contamination risks.

Unparalleled Safety Standards

An exceptional feature of the Korsch X3 is its enhanced safety measures designed to protect the workforce during production. The press is fitted with glove openings at the front and both sides, along with a specialized spray system that binds any residual dust after a batch is completed. This innovation significantly lowers the risk of airborne toxins, ensuring a safer environment for employees.

The local team received thorough on-site training from Korsch to handle the new press safely and expertly. This training ensures that the operators can maximize the benefits of the Korsch X3 while maintaining the highest safety standards.

Future Perspectives

The installation of the Korsch X3 has positioned Morpeth to meet the increasing demand for personalization and complexity in pharmaceutical therapies. Fully operational and compliant, this press is not only a testament to Piramal's ongoing commitment to excellence but also strengthens the company’s ability to supply life-saving treatments in essential therapy areas.

Piramal Pharma Solutions, with its integrated global network, continues to expand its services, providing comprehensive development and manufacturing solutions across the entire lifecycle of pharmaceuticals. The commitment to quality and innovation remains at the heart of its mission as it seeks to improve patient outcomes worldwide.

For more information about Piramal Pharma Solutions and its offerings, visit Piramal Pharma.